U.S. PURCHASERS' QUESTIONNAIRE

METHIONINE FROM FRANCE, JAPAN, AND SPAIN

This questionnaire must be received by the Commission by March 26, 2021

See last page for filing instructions.

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its antidumping investigations concerning methionine from France, Japan, and Spain (Inv. Nos. 731-TA-1534-1536 (Final)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your possession (19 U.S.C. § 1333(a)). Further information on this questionnaire can be obtained from Pamela Davis (202-205-2218, pamela.davis@usitc.gov).

	Address									
	City			State		Zip Code				
	Website _	Website								
	Has your firm purchased, or imported for its own use or retail sale, methionine (as defined on next page) from <u>any</u> source (domestic or foreign) at any time since January 1, 2018?									
	NO (Sign the certification below and promptly return only this page of the questionnaire to the Commission)									
YES (Complete all parts of the questionnaire, and return the entire questionnaire to the Commission)										
	•		the U.S. Interropbox.usitc.go			nission <i>Drop</i>	Box by clicking on the	e		
				CERTIFICA	TION					
submittin informati	ng this certificion provided i	cation, I also <u>c</u>	rant consent for naire and throu	or the Commis	sion, an	d its employ	t and verification by the rees and contract perso import-injury proceedin	onnel, to use the		
proceedir personne reviews, Appendix	ng or other part of (a) for deve and evaluati or 3; or (ii) by U	roceedings may loping or main ons relating to J.S. governmen	to be disclosed to taining the reco	o and used: (i) ords of this or (s, personnel, a d contract pers	by the a related nd oper	Commission, d proceeding rations of th	est for information and its employees and Office or (b) in internal investing Commission including ersecurity purposes. I un	ces, and contract stigations, audits, g under 5 U.S.C.		
Name of .	Authorized O	fficial	Title of Author	ized Official			Date			
Signature	e		Phone				Email address			

PART I.—GENERAL INFORMATION

Background.--This proceeding was instituted in response to petitions filed on July 29, 2020, by Novus International, Inc., St. Charles, Missouri. Antidumping duties may be assessed on the subject imports as a result of these proceedings if the Commission makes an affirmative determination of injury, threat, or material retardation, and if the U.S. Department of Commerce ("Commerce") makes an affirmative determination of dumping. Questionnaires and other information pertinent to this proceeding are available at

https://www.usitc.gov/investigations/701731/2020/methionine france japan and spain/final.htm.

<u>Methionine</u> covered by these investigations is methionine and dl-Hydroxy analogue of dlmethionine, also known as 2-Hydroxy 4-(Methylthio) Butanoic acid (HMTBa), regardless of purity, particle size, grade, or physical form. Methionine has the chemical formula $C_5H_{11}NO_2S$, liquid HMTBa has the chemical formula $C_5H_{10}O_3S$, and dry HMTBa has the chemical formula $(C_5H_9O_3S)_2Ca$.

Subject merchandise also includes methionine processed in a third country including, but not limited to, refining, converting from liquid to dry or dry to liquid form, or any other processing that would not otherwise remove the merchandise from the scope of these investigations if performed in the country of manufacture of the in-scope methionine or dl-Hydroxy analogue of dl-methionine.

The scope also includes methionine that is commingled (i.e., mixed or combined) with methionine from sources not subject to these investigations. Only the subject component of such commingled products is covered by the scope of these investigations.

Excluded from this investigation is United States Pharmacopoeia (USP) grade methionine. In order to qualify for this exclusion, USP grade methionine must meet or exceed all of the chemical, purity, performance, and labeling requirements of the United States Pharmacopeia and the National Formulary for USP grade methionine.

Methionine is currently classified under subheadings 2930.40.0000 and 2930.90.4600 of the Harmonized Tariff Schedule of the United States (HTSUS). Methionine has the Chemical Abstracts Service (CAS) registry numbers 583-91-5, 4857-44-7, 59-51-8 and 922-50-9. While the HTSUS subheadings and CAS registry numbers are provided for convenience and customs purposes, the written description of the scope of this investigation is dispositive.

DLM -- DL-methionine

MHA -- DL-Hydroxy analogue of DL-methionine

<u>Reporting of information</u>.—If information is not readily available from your records, provide carefully prepared estimates. If your firm is completing more than one questionnaire (i.e., a producer, importer, and/or purchaser questionnaire), you need not respond to duplicated questions.

<u>Confidentiality</u>.--The commercial and financial data furnished in response to this questionnaire that reveal the individual operations of your firm will be treated as confidential by the Commission to the extent that such data are not otherwise available to the public and will not be disclosed except as may be required by law (see 19 U.S.C. § 1677f). Such confidential information will not be published in a manner that will reveal the individual operations of your firm; however, general characterizations of numerical business proprietary information (such as discussion of trends) will be treated as confidential business information only at the request of the submitter for good cause shown.

<u>Verification</u>.--The information submitted in this questionnaire is subject to audit and verification by the Commission. To facilitate possible verification of data, please keep all files, worksheets, and supporting documents used in the preparation of the questionnaire response. Please also retain a copy of the final document that you submit.

Release of information.--The information provided by your firm in response to this questionnaire, as well as any other business proprietary information submitted by your firm to the Commission in connection with this proceeding, may become subject to, and released under, the administrative protective order provisions of the Tariff Act of 1930 (19 U.S.C. § 1677f) and section 207.7 of the Commission's Rules of Practice and Procedure (19 CFR § 207.7). This means that certain lawyers and other authorized individuals may temporarily be given access to the information for use in connection with this proceeding or other import-injury proceedings conducted by the Commission on the same or similar merchandise; those individuals would be subject to severe penalties if the information were divulged to unauthorized individuals.

<u>D-GRIDS tool.</u>--The Commission has a tool that firms can use to move data from their own MS Excel compilation files into self-contained data tables within this MS Word questionnaire, thereby reducing the amount of cell-by-cell data entry that would be required to complete this form. This tool is a macroenabled MS Excel file available for download from the Commission's generic questionnaires webpage (https://www.usitc.gov/trade_remedy/question.htm) called the "D-GRIDs tool." Use of this tool to help your firm complete this questionnaire is *optional*. Firms opting to use the D-GRIDs tool to populate their data into this questionnaire will need the D-GRIDs specification sheet PDF file specific to this proceeding (available on the case page which is linked under the "Background" above) which includes the necessary references relating to this questionnaire, as well as the macro-enable MS Excel D-GRIDs tool itself from the generic questionnaires page. More detailed instructions on how to use the D-GRIDs tool are available within the D-GRIDs tool itself.

I-1a.	<u>Establishments covered</u> Provide the name and address of your U.S. establishment(s) covered by this questionnaire, if different from that listed on the cover page. Firms operating more than one establishment should combine the data for all establishments into a single response.							
	"Establishment" Each facility of a firm involved in the <u>purchase</u> of methionine, including auxiliary facilities operated in conjunction with (whether or not physically separate from) s facilities.							
I-1b.	Stock symbol information stock exchange and trading sy	f your firm or parent firm is publicly to ymbol:	raded, please specify the					
I-1c.	<u>External counsel.</u> — If your firm or parent firm is represented by external counsel in relation to this proceeding, please specify the name of the law firm and the lead attorney(s).							
	Law firm:							
	Lead attorney(s):							
I-2.	OwnershipIs your firm owned, in whole or in part, by any other firm? No YesList the following information, relating to the ultimate parent/owner.							
	Firm name	Country	Extent of ownership (percent)					
	THIN HAME	Country	(percent)					
I-3.		Does your firm have any related firr nine into the United States or which e	-					
	☐ No ☐ YesList t	he following information.						
	Firm name	Country	Affiliation					

<u>Related producers</u> Does your firm have any related firms, either domestic or foreign, which produce methionine?						
□ No □ Yes	No YesList the following information.					
Firm name	Country	Affiliation				

PART II.--PURCHASES

<u>Contact information.</u>--Please identify the responsible individual and the manner by which Commission staff may contact that individual regarding the confidential information submitted in this questionnaire.

Name	
Title	
Email	
Telephone	

II-1. <u>Purchases and imports.--</u>Report <u>separately</u> your firm's domestic purchases and imports of methionine.

"Purchase" – Purchase from a U.S. entity such as a U.S. producer, a U.S. importer, or other U.S. firm.

"Import" – Purchase directly from a foreign supplier and your firm is the importer of record.

	2018	2019	2020	2018	2019	2020
Item	Quantity	Quantity of MHA (in short tons)		Quantity of DLM (in short tor		hort tons)
Purchases of methionine produced in— United States						
France						
Japan						
Spain						
All other countries ¹						
Sources unknown ²						
Total purchases	0	0	0	0	0	0
Imports of methionine from— France						
Japan						
Spain						
All other countries ¹						
Total imports ³	0	0	0	0	0	0
¹ Please identify these c	ountries:					

¹ Please identify these countries: _____.

² Please indicate the firm(s) from which you purchased this merchandise: _____.

³ If your firm imported methionine at any time since January 1, 2018, please also complete and return a U.S. importers' questionnaire in this proceeding.

II-2. <u>Changes in purchasing patterns.</u>--Please indicate how the shares of your firm's purchases of methionine from different sources have changed since January 1, 2018.

Source of purchases	Increased	Constant	Decreased	Fluctuated	Explanation for trend	Did not purchase
United States						
France						
Japan						
Spain						
All other countries						
Sources unknown						

II-3. <u>Country knowledge.</u>--Please indicate the countries of origin with which your firm has experience or information in the methionine market.

United States	France	Japan	Spain	Other countries	Other countries (specify)

II-4. <u>Supplier identification</u>.--Please list your firm's <u>FIVE</u> largest suppliers for methionine since January 1, 2018. Also, provide the share of the quantity of your firm's total purchases of methionine that each of these suppliers accounted for in 2020.

No.	Supplier's name	City and state	Share of quantity of 2020 purchases
1			%
2			%
3			%
4			%
5			%

PART III.--MARKET CHARACTERISTICS AND PURCHASING PRACTICES

Distribut	or End	d user:	Other:
ompetit	on for s	er of methionine, please answer questalesDoes your firm compete for a which your firm purchases methic	sales to customers with the man
No	Yes	If yes, please describe.	
ш			

If your firm is an end user of methionine, please answer questions III-4 and III-5.

III-4. <u>End uses.</u>--List the top 3 products your firm makes using methionine and estimate the percent of your <u>total production cost</u> that is accounted for by methionine and by other inputs (such as labor, energy, and other raw materials).

	Share of total cost in each of the product(s) your firm produces accounted for by				Total (should
Product(s) your firm produces	Methionine		Other inputs		sum to 100.0% across)
	%	+	%	=	0.0 %
	%	+	%	Ш	0.0 %
	%	+	%	II	0.0 %

III-5.	Demand for end-use	products

(a) Has the demand for your firm's final products that use methionine (feed, livestock, etc.) changed since January 1, 2018?

Increased	No change	Decreased	Fluctuated			
What are these final demand products?						

(b) Has this had any effect on your firm's demand for methionine?

No	Yes	Explain

	L	No		YesPle	ease fill out	the tak	ole.	
			E	hich this		Have changes in the price of this substitute affected the price for methionine?		
	Substitut	e	substitute is used			No	Yes	Explanation
1.								
2.								
3.								
III-7.	States (if	known) the princ	for me	thionine ha	s changed :	since Ja ed these	nuary	States and outside of the United 1, 2018. Explain any trends and ges in demand (including any effects
	States (if describe	known) the prince 1-19).	for me	thionine ha	s changed :	since Ja ed these Fluct	e char tuate	1, 2018. Explain any trends and ages in demand (including any effects
Ma	States (if describe of COVID	known) the prince 1-19).	for me cipal fa	thionine ha ctors that h	es changed s nave affecte Overall	since Ja ed these Fluct witl	e char tuate	1, 2018. Explain any trends and ages in demand (including any effects
M a n the Un	States (if describe of COVID	known) the prince 1-19).	for me cipal fa	thionine ha ctors that h	es changed s nave affecte Overall	since Ja ed these Fluct witl	e char tuate	1, 2018. Explain any trends and ages in demand (including any effects
M a n the Un	States (if describe of COVID or COVID o	known) the prince -19). Ovince [erall rease	No change	Overall decrease	Fluct with clear	tuate h no trend	Explanation and factors Explanation and factors ifically order methionine from one
Ma the Un le the U	States (if describe of COVID or COVID o	known) the prince -19). Ovince [erall rease	No change	Overall decrease	Fluct with clear	tuate h no trend	Explanation and factors Explanation and factors ifically order methionine from one

III-9.	Importance of purchasing domestic productPlease fill out the table below, estimating the
	percentage of your firm's total 2020 purchases of methionine that required methionine
	produced in the United States.

	Estimated percentage of your firm's total 2020 purchases of methionine
Purchases that did not require domestic product	%
Purchases that were required by law or regulation to be domestic product (e.g., government purchases under "Buy American" provisions)	%
Purchases that were not required by law or regulation, but were required by your customers to be domestic product	%
Purchases that were required to be domestic product for other reasons	
(explain:)	%
Total (should sum to 100.0%)	0.0 %

III-10. Conditions of competition.--

(a) Is the methionine market subject to business cycles and/or other conditions of competition distinctive to methionine?

Check a	ll that apply.	Please describe.
	No	Skip to question III-11.
	Yes-Business cycles (e.g. seasonal business)	
	Yes-Other distinctive conditions of competition	

(b) Have there been any changes in the business cycles or conditions of competition for methionine since January 1, 2018?

No	Yes	If yes, describe.

110	Durchacare'	Questionnaire	- Mothionina	(Einal)
U.S.	Purchasers	Questionnaire	- ivietnionine	(Final)

III-11.	Decisions based on producer and country-of-originHow often does your firm, and if known,
	do your customers, make purchasing decisions involving methionine based on its producer or
	country of origin?

Item	Always	Usually	Sometimes	Never	If at least sometimes, explain.	
Decision based on producer						
Your firm						
Your customers						
Decision based on country of origin						
Your firm						
Your customers						

III-12. **Availability of supply.--**Has the availability of methionine in the U.S. market changed since January 1, 2018?

Availability in the U.S.			Please explain, noting the countries and reasons for the
market	No	Yes	changes.
U.Sproduced product			
Subject imports			
Nonsubject imports			

III-13. <u>Supply constraints.</u>--Has any firm refused, declined, or been unable to supply your firm with methionine since January 1, 2018 (examples include placing customers on allocation or "controlled order entry," declining to accept new customers or renew existing customers, delivering less than the quantity promised, being unable to meet timely shipment commitments, etc.)?

No	Yes	If yes, please describe.

III-14. **Availability of specific product types.--**Are certain grades/types/forms of methionine only available from certain country sources?

No	Yes	If yes, please identify the countries and the grade/type/size.

U.S. Purchasers' Questionnaire - Methionine (Fig.	nal
---	-----

III-13. Puitilasilig liequelity	III-15.	Purchasing 1	frequency
---------------------------------	---------	--------------	-----------

(a١	How frequentl	v does v	our firm r	nake n	urchases c	of methionine	(check one)?	γ
١	u	TIOW ITCHACTIO	y accs y	oui illiii	Hake p	ui ciiases e		CHICCK OHCH	,

Daily	ily Weekly Monthly		Quarterly	Annually	Other	If other, specify

(b) Has this purchasing frequency changed since January 1, 2018?

No	Yes	If yes, please describe.

III-16. Raw material prices.—

(a) Is your firm familiar with the prices for raw materials used in the production of methionine?

No	Yes – please answer (b)

(b) Has information on raw material prices affected your firm's negotiations or contracts to purchase methionine since 2018?

No	Yes	Explain

III-17. <u>Price indices.</u>—Does your firm refer to or otherwise rely on any published price information, e.g., pricing indicators or any other sources, when negotiating spot or contract prices with your methionine suppliers? (Respond yes to all types of purchases in which you use published pricing information).

No	Yes for spot prices	If "Yes," identify the source(s) on which you rely for this methionine pricing, the specific pricing data set(s) you use from these sources, and how that information is used in your firm's pricing decisions.

U.S.	Purchasers'	Questionnaire -	Methionine	(Final)

III-18.	. Non-U.S. prices.—								
	(a) Is your firm familiar with non-U.S. prices of methionine?								
	No Yes – please answer (b)								
	(b) Are non-U.S. prices referenced in negotiations with your methionine suppliers?								
			No	Yes	Explain, noting	g what price(s) are referenced		
		-	ntity of I	-				markets, please report the markets in 2020 in short	
			Quanti	ity of I	VIHA (in short t	ons)	Quantity of D	LM (in short tons)	
		Are price	-	ces gei	nerally higher th	nan, about the	same as, or low	er than non-U.S. methionine	
				Hi	gher	About	the same	Lower	
				[
	(e)	Do l	J.S. pric	e chan	ges lead, trail, o	or move simul	taneously with n	on-U.S. prices?	
Move count							countries of cor	would differ among mparison, please list those he difference(s).	
	(f) Since January 1, 2018 what are the major factors that have influenced non-U.S. prices?								
			No	Yes	Explain, noting	g what price(s) your firm refer	enced	

40				
III-19.	Price	determi	ınatıon.	

,	۱ ـ ۱	D		A 44114	Lacrada coda a la					£
(a)	DO y	ou consider	activity	ieveis when	comparing	prices	among	sources o	f methionine?

N	No – skip to III-20	Yes	Please explain.

(b) Does your firm consider the bioefficacy as equal to or less than the activity level of the methionine?

Equal	Less than	If "less than," at what bioefficacy level do you treat the methionine you purchase when negotiating prices?

(c) When controlling for activity levels, are methionine products of different activity levels comparable?

Fully	Mostly	Somewhat	Not at all

		11.00	<i>"</i> • • • • •	"	
(H)	If your answer	ditters than	"tully" or	"mostly"	nlease explain

III-20.	-				•		on Chinese-origin products under e United States?
	Yes — Please indicate the impact in the table below.				No		Don't know
]				
	Factor		Overall increase	No change	Overall decrease	Fluctuate with no clear trend	Explain, noting how the imposition of tariffs under section 301 affected each factor of the methionine market in the United States.
	ply of U.S ed methic						
	of methic						
Supply of methionine imported from France							
	of methic ed from J						
	of methic						
Prices f	or methic	onine					
	l U.S. den methionir						
	aterial cos ethionine						
	III-21. (a) Number of suppliers contacted (contract)How many suppliers does your firm generally contact before making a contract purchase? Between and firms (g) Number of suppliers contacted (spot)How many suppliers does your firm generally contact before making a spot purchase? Between and firms						
	No	Yes	_	-	-	_	rally negotiates and note whether g negotiations.

119	Durchasers'	Questionnaire	- Methionine	(Final)
υ.:	o, Pulchaseis	Questionnaire	- weumonine	(FIIIdI <i>)</i>

III-23.	Bundling.—
---------	------------

Do you purchase methionine as a part of multiple products related to agricultural

No	Yes	products or prices	your firm purchases	e invoice? Please explain what other in the same order, if it affects the part of a global, multiproduct
		No	Yes	

III-24. Change in suppliers.--Has your firm changed suppliers since January 1, 2018?

No	If yes, please list the supplier(s), whether the firm was added or dropped, and the reasons for the change.

III-25. Multiple supply sources.—

- (a) How many suppliers of methionine have you purchased from since January 1, 2018?
- (b) Have you maintained multiple suppliers of methionine since January 1, 2018?

No	Yes	If yes, when did you begin using multiple suppliers, and what types of methionine did each supply (dry/liquid, DLM/MHA, activity level)?

(c) How important is maintaining more than one supply source of methionine?

Very important	Important	Moderately important	Slightly important	Not at all important

III-26. New suppliers.--Are you aware of any new suppliers, either foreign or domestic, that have entered the market since January 1, 2018?

No	Yes	If yes, please identify the firms.

III-27.	Supplier qualificationDo you require your suppliers to be or to become certified or qualified
	to sell methionine to your firm?

If yes, provide the following information.

- The number of days to qualify a new supplier.
- A general description of the certification or qualification process. Also, a brief description of the factors that you consider when qualifying a new supplier (e.g., quality of product, reliability of supplier, etc.).

No	Number of days	Process and factors

III-28. <u>Failure to certify</u>.--Since January 1, 2018, have any domestic or foreign producers failed in their attempts to certify or qualify their methionine with your firm or have any producers lost their approved status?

No	If yes, please identifbudly these firms, the countries where they are located, and the reasons why they failed the certification/qualification.

III-29. <u>Major purchasing factors</u>.--Please list, in order of their importance, the main factors your firm considers in deciding from whom to purchase methionine (examples include availability, extension of credit, contracts, price, quality, range of supplier's product line, traditional supplier, etc.).

1.		
2.		
3.		
Please	e list any other factors that are very important in your purchase decisions:	

III-31.

III-30. <u>Purchasing factors.</u>—Please rate the importance of the following factors in your firm's purchasing decisions for methionine.

Factor	Very important	Somewhat important	Not important	
Availability				
Bioefficacy				
Delivery terms				
Delivery time				
Discounts offered				
Minimum quantity requirements				
Packaging				
Payment terms				
Price				
Product consistency				
Product range				
Quality meets industry standards				
Quality exceeds industry standards				
Reliability of supply				
Technical support/service				
U.S. transportation costs				
Quality characteristicsWhat characteristics does your firm consider when evaluating the quality of methionine?				

115	Durchacars'	Ouestionnai	re - Methionine	(Final)
U.S.	Purchasers	Questionnaii	re - ivietnionine	(Final

III-32.	Minimum qualityHow often does methionine from the following countries meet minimum
	quality specifications for your uses or your customers' uses?

Source	Always	Usually	Sometimes	Rarely or never	Don't know
United States					
France					
Japan					
Spain					
Other:					

III-33.	Frequency of decisions based on priceHow often does your firm purchase the methionine
	that is offered at the lowest price?

Always	Usually	Sometimes	Never

III-34. **Price leaders.**--A price leader is defined as (1) one or more firms that initiate a price change, either upward or downward, that is followed by other firms, or (2) one or more firms that have a significant impact on prices. A price leader is not necessarily the lowest-priced supplier.

Please list the names of any firms you considered price leaders in the methionine market since January 1, 2018.

Firm(s)	Describe how the firm(s) exhibited price leadership

III-35. <u>Decisions based on type</u>.-- What is the reason(s) for purchasing the type of methionine you currently purchase (e.g., dry/liquid, MHA/DLM, activity level)?

Type purchased	Describe the reason(s)

115	Durchacars'	Questionnaire	- Mathionina	(Einal)
U.S.	Pulcilaseis	Questionnaire	- weumonine	(Fillai)

	No	Yes	Please descri	be the tim	e and cost ne	cessary t	o switch
Dry vs. liquid							
DLM vs. MHA							
Different activity level	$ \Box $						
·	_How	interch	angeable are o	lifferent ty	nes of methic	onine for	vour
ype interchangeability.	—How	interch	ı		· I	T	T
Type interchangeability. application(s)?			angeable are of Completely	different ty	pes of methic	T	T
Type interchangeability.	84% M	HA	ı		· I	T	your Not at a

III-38. Purchasing subject imports rather than domestic products.—

(a)	Since January 2018, did your firm import and/or purchase imports of methionine from
	France, Japan, and/or Spain instead of purchasing U.Sproduced methionine?

Source	Yes (also respond to parts (b) and (c))	No (If "No" for all countries, skip to next question)
France		
Japan		
Spain		

(b) If you responded "Yes" to part (a), was the imported product priced lower than the domestic product?

Source	Yes	No
France		
Japan		
Spain		

(c) If you responded "Yes" to part (a), was price a primary reason for importing and/or purchasing subject imports rather than domestic product?

Source	Yes	If Yes, estimate the quantity of imports purchased and/or imported instead of domestic product since January 2018 (in short tons)	No	If No, please indicate the reason your firm imported and/or purchased imports instead of domestic product
France				
Japan				
Spain				

III-39. <u>U.S. producers and import competition</u>.—

(a) Since January 1, 2018, in connection with a sale or offer to sell methionine to your firm, did U.S. producers reduce their prices of domestically produced methionine in order to compete with lower-priced imports of methionine from the subject countries? Respond for each subject country.

Source	Yes (also respond to question part (b))	No (If "No" for all countries, skip to next question)	Don't know
France			
Japan			
Spain			

(b) If your firm responded "yes" to any of the above countries, please provide an estimate of the reduction in U.S. producers' prices and any additional explanations.

Source	Estimated reduction in U.S. prices (percent)	Additional explanation, including such information as timing (e.g., months/years), frequency of price reductions, or other market/competitive factors
France	%	
Japan	%	
Spain	%	

PART IV.—PRODUCT COMPARISONS

Interchangeability.--Is methionine produced in the United States and in other countries IV-1. interchangeable (i.e., can they physically be used in the same applications)?

Please indicate A, F, S, N, or 0 in the table below:

- A = the products from a specified country-pair are *always* interchangeable
- F = the products are *frequently* interchangeable
- S = the products are *sometimes* interchangeable
- N = the products are *never* interchangeable
- 0 = no familiarity with products from a specified country-pair

Country-pair	France	Japan	Spain	Other countries
United States				
France				
Japan				
Spain				
	y-pair producing met the country-pair and			

the country-pair and explain the factors that limit or preclude interchang use:

IV-2. <u>Factors other than price.</u>--Are differences other than price (e.g., quality, availability, transportation network, product range, technical support, *etc.*) between methionine produced in the United States and in other countries a significant factor in your firm's purchases of the products?

Please indicate A, F, S, N, or 0 in the table below:

A = such differences are *always* significant

F = such differences are *frequently* significant

S = such differences are *sometimes* significant

N = such differences are *never* significant

0 = *no familiarity* with products from a specified country-pair

Country-pair	France	Japan	Spain	Other countries
United States				
France				
Japan				
Spain				

For any country-pair for which factors other than price *always* or *frequently* are a significant factor in your firm's purchases of methionine, identify the country-pair and report the advantages or disadvantages imparted by such factors:

prices/U.S. transportation costs than the second country.

IV-3. <u>Factor country comparisons.</u>--For the factors listed below, please rate how methionine produced in each country you identified in your response to the first question in Part IV compares with methionine produced in each of the other countries you identified.

	Product from <u>United States</u> compared to product from <u>France</u>				Product from <u>United States</u> compared to product from <u>Japan</u>				<u>Uni</u> coi	Product from United States compared to product from Spain		
Factor	Superior	Comparable	Inferior		Superior	Comparable	Inferior		Superior	Comparable	Inferior	
Availability												
Bioefficacy												
Delivery terms												
Delivery time												
Discounts offered												
Minimum quantity requirements												
Packaging												
Payment terms												
Price ¹												
Product consistency												
Product range												
Quality meets industry standards												
Quality exceeds industry standards												
Reliability of supply												
Technical support/service												
U.S. transportation costs ¹												
¹ A rating of "superior" on price and U.S. transportation costs indicates that the first country generally has lower												

prices/U.S. transportation costs than the second country.

IV-3. **Continued.**

	Product from France compared to product from Japan			Product from France compared to product from Spain				Product from <u>Japan</u> compared to product from <u>Spain</u>		
Factor	Superior	Comparable	Inferior	Superior	Comparable	Inferior		Superior	Comparable	Inferior
Availability										
Bioefficacy										
Delivery terms										
Delivery time										
Discounts offered										
Minimum quantity requirements										
Packaging										
Payment terms										
Price ¹										
Product consistency										
Product range										
Quality meets industry standards										
Quality exceeds industry standards										
Reliability of supply										
Technical support/service										
U.S. transportation costs ¹										

IV-3. **Continued.**

	<u>L</u> compar	Product from United State ed to produ Subject cour	e <u>s</u> ict from		Product from <u>France</u> compared to product from <u>Nonsubject countries</u>			
Factor	Superior	Comparable	Inferior		Superior	Comparable	Inferior	
Availability								
Bioefficacy								
Delivery terms								
Delivery time								
Discounts offered								
Minimum quantity requirements								
Packaging								
Payment terms								
Price ¹								
Product consistency								
Product range								
Quality meets industry standards								
Quality exceeds industry standards								
Reliability of supply								
Technical support/service								
U.S. transportation costs ¹								
¹ A rating of 'superior" on price	and U.S. tran	sportation co	osts indicates	that the	e first count	ry generally	has lower	

¹ A rating of 'superior" on price and U.S. transportation costs indicates that the first country generally has lower prices/U.S. transportation costs than the second country.

IV-3. **Continued.**

	compar	Product from Japan ed to produ subject cour	ıct from	Product from <u>Spain</u> compared to product from <u>Nonsubject countries</u>			
Factor	Superior	Comparable	Inferior	Superior	Comparable	Inferior	
Availability							
Bioefficacy							
Delivery terms							
Delivery time							
Discounts offered							
Minimum quantity requirements							
Packaging							
Payment terms							
Price ¹							
Product consistency							
Product range							
Quality meets industry standards							
Quality exceeds industry standards							
Reliability of supply							
Technical support/service							
U.S. transportation costs ¹							

¹ A rating of 'superior" on price and U.S. transportation costs indicates that the first country generally has lower prices/U.S. transportation costs than the second country.

PART V.—ADDITIONAL INFORMATION

V-1.	Other explanationsIf your firm would like to further explain a response to any question that
	for which a narrative response box was not provided, please note the question number and the
	explanation in the space provided below.

V-2. <u>OMB statistics</u>.--Please report the actual number of hours required and the cost to your firm of completing this questionnaire.

Hours	Dollars

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 25 hours per response, including the time for reviewing instructions, gathering data, and completing and reviewing the questionnaire.

We welcome comments regarding the accuracy of this burden estimate, suggestions for reducing the burden, and any suggestions for improving this questionnaire. Please attach such comments to your response or send to the Office of Investigations, USITC, 500 E St. SW, Washington, DC 20436.

HOW TO FILE YOUR QUESTIONNAIRE RESPONSE

This questionnaire is available as a "fillable" form in MS Word format on the Commission's website at:

https://www.usitc.gov/investigations/701731/2020/methionine_france_japan_and_spain/final.htm

Please do not attempt to modify the format or permissions of the questionnaire document. Please submit the completed questionnaire using one of the methods noted below. If your firm is unable to complete the MS Word questionnaire or cannot use one of the electronic methods of submission, please contact the Commission for further instructions.

• <u>Upload via Secure Drop Box</u>.—Upload the MS Word questionnaire along with a scanned copy of the signed certification page (page 1) through the Commission's secure upload facility:

Web address: https://dropbox.usitc.gov/oinv/ Pin: MET

• E-mail.—E-mail the MS Word questionnaire to pamela.davis@usitc.gov; include a scanned copy of the signed certification page (page 1). Submitters are strongly encouraged to encrypt nonpublic documents that are electronically transmitted to the Commission to protect your sensitive information from unauthorized disclosure. The USITC secure drop-box system and the Electronic Document Information System (EDIS) use Federal Information Processing Standards (FIPS) 140-2 cryptographic algorithms to encrypt data in transit. Submitting your nonpublic documents by a means that does not use these encryption algorithms (such as by email) may subject your firm's nonpublic information to unauthorized disclosure during transmission. If you choose a non-encrypted method of electronic transmission, the Commission warns you that the risk of such possible unauthorized disclosure is assumed by you and not by the Commission.

If your firm <u>does not </u>**purchase this product**, please fill out page 1, print, sign, and submit a scanned copy to the Commission.

<u>Parties to this proceeding</u>.—If your firm is a party to this proceeding, it is required to serve a copy of the completed questionnaire on parties to the proceeding that are subject to administrative protective order (see 19 CFR § 207.7). A list of such parties may be obtained from the Commission's Secretary (202-205-1803). A certificate of service must accompany the completed questionnaire your firm submits (see 19 CFR § 207.7). Service of the questionnaire must be made in paper form.